Compare PDD Holdings Inc. American Depositary Shares (PDD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PDD Holdings Inc. American Depositary Shares vs Repligen Corporation Common Stock — how do they compare? PDD Holdings Inc. American Depositary Shares trades at $80 (market cap $116.66B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: PDD Holdings Inc. American Depositary Shares is far larger — about 10.5× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, PDD Holdings Inc. American Depositary Shares nearer its low. Which is the better fit depends on your goals.
| PDD | RGEN | |
|---|---|---|
Market Cap | $116.66B | $11.14B |
Volume | 9,095,378 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $138.13 | $194.57 |
52-Week Low | $73.30 | $102.87 |
Enterprise Value | $49.19B | $11.02B |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDD Holdings trades at $81.96, up 1.29% with a bullish technical signal despite recent earnings volatility. The stock shows strong fundamentals with a P/E of 8.81 and robust profitability margins (net income margin 20.43%). Recent news highlights investor attention and the company's major investment cycle while facing regulatory and competitive pressures.
The outlook remains cautiously optimistic with a $99.13 consensus price target, though risks include trade policy impacts and execution challenges from PDD's shift to an asset-heavy model. Earnings misses in recent quarters and moderating revenue growth warrant close monitoring for sustained investor confidence.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PDD Holdings Inc. American Depositary Shares
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. Its sourcing, logistics, and fulfillment network supports those businesses and their commerce operations.
Read more on PDD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
